Course: WB 4342
CE Original Date: March 20, 2020
CE Renewal Date: March 20, 2022
CE Expiration Date: March 20, 2024
Download Printer-Friendly version [PDF – 911 KB]
- Ethylene glycol ingestion first affects the central nervous system (CNS). After a characteristic latent period, toxic metabolites might produce signs of inebriation followed by serious illness and even death.
- No studies were located regarding a link between ethylene glycol exposure and cancer or reproductive or developmental hazards in humans.
- Propylene glycol is much less toxic than ethylene glycol.
This educational case study is one in a series of self-instructional modules designed to increase the primary care provider’s knowledge of hazardous substances in the environment. The modules also promote adoption of medical practices that aid in the evaluation and care of potentially exposed patients. You can access the complete series of Case Studies in Environmental Medicine on the Agency for Toxic Substances and Disease Registry (ATSDR) website at URL: https://www.atsdr.cdc.gov/emes/health_professionals/index.html.
A downloadable PDF [PDF – 911 KB] version of this educational series and other environmental medicine materials provides content in an electronic, printable format, especially for those who might lack adequate Internet service.
We gratefully acknowledge the work of the medical writers, editors, and reviewers in producing this educational resource. Listed below are the contributors to this version of the Case Study in Environmental Medicine.
Please Note: Each content expert for this case study has indicated that there is no conflict of interest to disclose that would bias the case study content.
ATSDR Authors: Dianyi Yu, MD
ATSDR Planners: Charlton Coles, PhD; Sharon L. Hall, PhD; Julia Smith, MPH, CHES
Peer Reviewers: Obaid Faroon, DVM, PhD, and Ki Moon Bang, PhD, MPH
ATSDR Commenters: Alaina Steck, MD
To receive free continuing education, please visit the CSEM Ethylene Glycol/Propylene Glycol Toxicity registration page
In compliance with continuing education requirements, all planners and presenters must disclose all financial relationships, in any amount, with ineligible companies during the previous 24 months as well as any use of unlabeled product(s) or products under investigational use.
CDC, our planners, and content experts wish to disclose they have no financial relationship(s) with ineligible companies whose primary business is producing, marketing, selling, reselling, or distributing healthcare products used by or on patients.
Content will not include any discussion of the unlabeled use of a product or a product under investigational use.
CDC did not accept financial or in-kind support from ineligible companies for this continuing education activity.
U.S. Department of Health and Human Services
Agency for Toxic Substances and Disease Registry
Division of Toxicology and Environmental Medicine
Environmental Medicine and Educational Services Branch